Omegaven® as Parenteral Nutrition

Overview

The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.

Full Title of Study: “Omegaven® as Parenteral Nutrition”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2017

Interventions

  • Drug: Omegaven
    • Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.

Arms, Groups and Cohorts

  • Other: Omegaven

Clinical Trial Outcome Measures

Primary Measures

  • Primary Outcomes/Endpoints ( time from baseline until the patient normalizes bilirubin (presents three consecutive direct bilirubin ≤ 2 mg/dL or a direct bilirubin ≤ 2 mg/dL and weaned from PN)
    • Time Frame: Until weaned from PN
    • Primary efficacy analysis will include time from baseline until the patient normalizes bilirubin (presents three consecutive direct bilirubin ≤ 2 mg/dL or a direct bilirubin ≤ 2 mg/dL and weaned from PN).

Secondary Measures

  • Growth (weight three times per week, length once weekly, and head circumference)
    • Time Frame: Until weaned from PN
    • At a minimum, monitoring of growth parameters while on Omegaven® will include weight three times per week, length once weekly, and head circumference once weekly.
  • Essential Fatty Acids (evidence of essential fatty acid (EFA) deficiency)
    • Time Frame: Until weaned from PN
    • We will monitor infants who are not receiving any enteral feeding at all for more than 4 weeks for any evidence of essential fatty acid (EFA) deficiency.

Participating in This Clinical Trial

Inclusion Criteria

  • Greater than 14 days old. – Have PN-associated cholestasis defined as at least 2 consecutive direct bilirubin >2 mg/dL with anatomical or functional short gut (OR >4 mg/dL if intact intestine) obtained at least 1 week apart with a ratio of direct: total bilirubin > 0.4. – Patients will be PN dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require PN for at least 4 more weeks. – Patients must have failed standard therapies for Parenteral Nutrition Associated Liver Disease (PNALD) including: cycling of PN, avoiding overfeeding, reduction/removal of copper and manganese from PN, advancement of enteral feeding, and use of ursodiol (i.e. Actigall). – Signed patient informed consent. – The patient is expected to have a reasonable possibility of survival. – No other known etiology of cholestasis other than PNALD at time of Omegaven® initiation. Exclusion Criteria:

  • Causes of cholestasis other than PNALD including but not limited to Hepatitis C, Cystic fibrosis, biliary atresia, and alpha 1 anti-trypsin deficiency, prior to Omegaven® initiation. – Known fish or egg allergy – Any of the contraindications to use of Omegaven®: 1. Active new infection at the time of initiation of Omegaven® 2. Hemodynamic instability 3. Use of medications with associated risk of bleeding, including nonsteroidal antiinflammatory drugs (NSAIDs) 4. Active coagulopathy or bleeding 5. Thrombocytopenia 6. Unstable hyperglycemia 7. Impaired lipid metabolism (triglycerides >1000 mg/dL) while on 1 g/kg/day or less of Intralipid 8. History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.) 9. Unstable diabetes mellitus 10. Collapse and shock 11. Stroke/ Embolism 12. Cardiac infarction within the last 3 months 13. Undefined coma status – Enrollment in a clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team) – The parent or guardian of child is unwilling to provide consent or assent

Gender Eligibility: All

Minimum Age: 14 Days

Maximum Age: 4 Months

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Carle Foundation Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • William Stratton, MD, Principal Investigator, Carle Foundation Hospital
  • Overall Contact(s)
    • Deveine Toney, (217) 326-4504, deveine.toney@carle.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.